Genetics of Bone and Muscle Interactions in Humans by Trajanoska, K. et al.
MUSCLE AND BONE (L BONEWALD AND M HAMRICK, SECTION EDITORS)
Genetics of Bone and Muscle Interactions in Humans
Katerina Trajanoska1 & Fernando Rivadeneira1 & Douglas P. Kiel2,3,4 & David Karasik2,5
Published online: 28 February 2019
# The Author(s) 2019
Abstract
Purpose of Review To summarize the evidence from recent studies on the shared genetics between bone and muscle in humans.
Recent Findings Genome-wide association studies (GWAS) have successfully identified a multitude of loci influencing the
variability of different bone or muscle parameters, with multiple loci overlapping between the traits. In addition, joint analyses
of multiple correlated musculoskeletal traits (i.e., multivariate GWAS) have underscored several genes with possible pleiotropic
effects on both bone and muscle including MEF2C and SREBF1. Notably, several of the proposed pleiotropic genes have been
validated using human cells or animal models.
Summary It is clear that the study of pleiotropy may provide novel insights into disease pathophysiology potentially leading to
the identification of new treatment strategies that simultaneously prevent or treat both osteoporosis and sarcopenia. However, the
role of muscle factors (myokines) that stimulate bone metabolism, as well as osteokines that affect muscles, is in its earliest stage
of understanding.
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Introduction
Osteoporosis and sarcopenia are common and costly co-
morbid diseases of aging, and there is an urgent need to
prevent and treat both to reduce their associated mor-
bidity and mortality [1••]. A burgeoning body of work
shows that they share many common risk factors and
biological pathways such as effects of growth hormone
and inflammatory cytokines [2, 3]. Moreover, the com-
mon mesenchymal origin of bone and muscle cells
underpins the tight link between these conditions from
the early stages of embryonic development.
Muscle mass and function are important determinants
of skeletal growth and bone mass accrual in growing
humans. This adaption of bone tissue to loading follows
the principles of Frost’s mechanostat theory, i.e., bone
growth and bone loss are stimulated by the muscle
forces/loads acting upon bone surfaces [4]. In addition
to their mechanical interaction, bone and muscle are
jointly regulated by hormones, and inextricably linked
genetically and molecularly [5]. However, the latter in-
teractions are difficult to observe and measure; thus,
their roles are less well recognized. The recent rise of
new technologies (arising from genetics, molecular biol-
ogy etc.) has shed new light on the genetic and molec-
ular interplay between bone and muscle; thus, our un-
derstanding of these interactions has evolved over time.
In the past few years, studies have endeavored to (1)
disentangle the intricate molecular mechanisms that lead
to osteoporosis and sarcopenia and (2) develop new
treatment strategies by pinpointing drug targets common
to both conditions.
The aim of this review is to summarize the evidence from
current studies on the shared genetics between bone and mus-
cle in humans. Another recent review has addressed this topic
in mouse models [6].
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Genome-Wide Association Study for Bone
or Muscle-Related Phenotypes
Risk factors affecting osteoporosis and sarcopenia have
a strong genetic component, with heritability estimates
above 60% [7]. Genome-wide association studies
(GWAS) have identified multiple genetic variants
influencing the variability of bone mass (Fig. 1). In
total, 62 loci [8–12] have been associated with DXA-
derived bone mineral density (BMD) at either the fem-
oral neck or lumbar spine, while 36 loci [13] have been
associated with total body BMD. Notably, these GWASs
have highlighted known bone-active pathways, i.e.,
OPG-RANK-RANKL, WNT, and mesenchymal differen-
tiation, among others [14]. One of the greatest successes
in the osteoporosis field was achieved through the dis-
covery of the BMD locus harboring WNT16, a critical
regulator of cortical bone thickness [15] and trabecular
bone mass [16]. Moreover, with an ever-growing num-
ber of genes discovered by GWASs, novel pathways
acting on bone have been identified (e.g., oncogenic
and melanogenesis pathways). Recently, 518 loci have
been associated with ultrasound-derived heel BMD [17,
18], estimated in more than 400,000 participants of the
UK Biobank (UKBB) study. Together, these studies
have provided new insights into the pathophysiology
of osteoporosis, illustrated by the discovery and func-
tional validation of GPC6 and DAAM2. GPC6 may
serve as novel drug target for osteoporosis, since it en-
codes glypican, which is involved in cellular growth
control and differentiation. Moreover, GPC6 loss of
function leads to increased bone mineral content and
developmental skeletal abnormalities. DAAM2 also may
be a potential drug target for osteoporosis as it shows
effects on bone strength, porosity, and quality in murine
models by indirect regulation of the canonical Wnt sig-
naling. DAAM2 was also expressed in human skeletal
muscle [19] (Table 1).
In contrast, the fewer number of GWAS of muscle-related
phenotype provide less biological insight about the pathways
leading to the development of sarcopenia (Fig. 1). To date,
only five loci (HSD17B11, VCAN, ADAMTSL3, IRS1, and
Fig. 1 Phenogram showing genome-wide association study results for
bone and muscle-related phenotypes. Genes mapping to loci associated
with lean mass (light blue), hand grip (light green), heel ultrasound
estimated BMD (red), and DXA-derived BMD (gray). The ideogram
was constructed using Phenogram http://visualization.ritchielab.psu.edu/
phenograms/plot
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FTO) have been robustly associated with lean mass (total and/
or appendicular) [20], which constitutes a good proxy for
skeletal muscle mass [21]. Three out of the five lean mass-
associated SNPs identified by GWAS are significantly
enriched in enhancers and promoters acting in muscle cells.
Recently, the same study identified TNRV6B as additional
lean mass locus after more stringent adjustment for fat [22].
However, the exact biological pathways affecting muscle
mass still remain unknown. Two recent grip strength
GWAS, a proxy for muscular function, have been more fruit-
ful, yielding 64 muscle strength-related loci [23, 24] identified
within the UK Biobank. The loci found associated with grip
strength contain genes implicated in the structure and function
of skeletal muscle (ACTG1), excitation-contraction coupling
(SLC8A1), or involvement in the regulation of neurotransmis-
sion (SYT1), which provides additional evidence of the genetic
control exerted on this muscle trait [23]. These findings high-
light that the grip strength phenotype has a neuromuscular
component, since it also characterizes the ability of the periph-
eral nervous system to appropriately recruit muscle cells.
Briefly, Actg1-ms knockout mice display muscle weakness
and whole-body functional deficit [25]. SLC8A1 overexpres-
sion in muscle cells induces muscular changes similar to those
of muscular dystrophy [26]. Finally, SYT1 has been linked to
synaptic defects at the neuromuscular junctions in mouse
model of spinal muscular atrophy [27]. Further, three lead
SNPs (rs10186876, rs6687430, and rs754512) for grip
strength map in the vicinity of genes implicated in monogenic
syndromes characterized by neurological and/or psychomotor
impairment like French-Canadian variant of Leigh syndrome
characterized (LRPPRC), Zellweger Spectrum Peroxisomal
Biogenesis Disorder (PEX14), and Koolen-de Vries syndrome
(KANSL1) [23].
From Cross-Phenotype Effects to Pleiotropy:
Bone and Muscle
Basic Concepts
Multiple genes identified by GWAS of muscle-related traits
have also been associated with heel BMD in the UKBB
GWAS (Table 2). While such cross-phenotype associations
may arise due to biological pleiotropy, there are other reasons
that can lead to spurious pleiotropy. Therefore, cross-
phenotype associations should not be always regarded as the
consequence of true pleiotropy. Pleiotropy commonly refers
to a phenomenon in which a genetic locus (a gene or a single
variant within a gene) affects more than one trait or disease
[28]. It can be classified as (1) biological—when a gene has a
direct biological effect onmore than one trait or biomarker; (2)
mediated—where a gene has a biological effect on one trait
which lies on the causal path to another trait and thus the gene
affects both traits; and (3) spurious—when different forms of
biases can lead to false-positive findings [29]. The most com-
mon causes of spurious pleiotropy are ascertainment bias and
phenotypic misclassification [29]. The study of pleiotropy
may have tremendous clinical implications in the fields of
osteoporosis and sarcopenia by discovering new drug targets
acting on both muscle and bone.
Table 1 Bone genes discovered
by UK Biobank (and other
GWAS) and evidence of their
molecular role in the muscle
eBMD gene Muscle-related trait Reference
AHNAK Gene expression in human skeletal muscle Su, Ekman et al. 2015
AQP1 Gene expression in human skeletal muscle Su, Ekman et al. 2015
ARHGAP26 Positive/mouse skeletal muscle mass KO Verbrugge, Schönfelder et al. 2018
BCKDHB Gene expression in human skeletal muscle Su, Ekman et al. 2015
DAAM2 Gene expression in human skeletal muscle Su, Ekman et al. 2015
DLEU1 Gene expression in human skeletal muscle Su, Ekman et al. 2015
GRB10 Negative/mouse skeletal muscle mass KO Verbrugge, Schönfelder et al. 2018
HMGA2 Positive/mouse skeletal muscle mass KO Verbrugge, Schönfelder et al. 2018
IGFBP2 Negative/mouse skeletal muscle mass overexpress Verbrugge, Schönfelder et al. 2018
MMP9 Positive/mouse skeletal muscle mass overexpress Verbrugge, Schönfelder et al. 2018
MPP7 Gene expression in human skeletal muscle Su, Ekman et al. 2015
PPARD Positive/mouse skeletal muscle mass overexpress Verbrugge, Schönfelder et al. 2018
SMAD3 Positive/ mouse skeletal muscle mass KO Verbrugge, Schönfelder et al. 2018
SMAD7 Positive/mouse skeletal muscle mass KO Verbrugge, Schönfelder et al. 2018
SOX6 Positive/mouse skeletal muscle mass KO Verbrugge, Schönfelder et al. 2018
eBMD estimated bone mineral density, KO knock out
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Shared Biology: Evidence from Multivariate Analysis
While GWAS are typically performed for the study of one trait
at a time, more recently methodological advances have en-
abled the simultaneous GWAS assessment of multiple traits.
In humans, joint analysis of multiple, correlated traits, i.e.,
multivariate GWAS, has been instrumental to the identifica-
tion of pleiotropic candidate SNPs/loci associated with traits
related to both bone and muscle metabolism. GWAS investi-
gating both bone and muscle phenotypes have produced a list
of potential candidate genes for further biological validation
such as PRKCH and SCNN1B [30] in 3844 Europeans; HK2,
UMOD,MIR873, andMIR876 [31] in 1627 unrelated Chinese
adults individuals; HTR1E, COL4A2, AKAP6, SLC2A11,
RYR3, and MEF2C [32]; and GLYAT [33] in 1627 unrelated
Chinese adults. In addition, the GWAS–identifiedMETTL21C
was found to be a novel pleiotropic gene suggestive of asso-
ciation with both muscle and bone acting through the modu-
lation of the NF-κB signaling pathway [34••]. This gene has
been implicated in the etiology of inclusion body myositis
(skeletal muscle) and of early-onset Paget’s disease (bone)
[35]. Subsequent studies confirmed thatMETTL21C polymor-
phisms contribute to peak bone mass in Chinese males [36].
Moreover, frail subjects showed higher expression levels of
METTl21C compared to young healthy older adults [37].
METTL21C belongs to the METTL21 family of the methyl-
transferase superfamily and possesses protein-lysine N-meth-
yltransferase activity [38]; its close homolog,METTL21Dwas
found to bind to the chaperone valosin-containing protein
(VCP, a.k.a. VCP/p97), known to play a role in a muscle
atrophy disease [39]. More recently, Medina-Gomez et al.
[40••] performed a bivariate GWAS meta-analysis of total
body lean mass and total body less head BMD in 10,414
children. The study identified variants with pleiotropic effects
in eight loci, mostly already known for BMD (WNT4,
GALNT3, MEPE, CPED1/WNT16, TNFSF11, RIN3, and
PPP6R3/LRP5), but also the TOM1L2/SREBF1 locus not pre-
viously associated with BMD or lean mass. The protein was
highly expressed in mouse calvaria-derived cells during os-
teoblastogenesis and showed the highest expression peak at
the onset of osteoblast mineralization in human mesenchymal
stem cells. Moreover, SREBP1 indirectly downregulated sev-
eral key regulators of myogenesis (i.e., MYOD1, MYOG,
MEF2C). Notably, SREBF1 exerted opposite effects on the
differentiation of myocytes and osteoblasts, which are in line
with the opposite effects observed on BMD and lean mass in
the bivariate analysis.
Human and Animal Bone-Focused Knock-out
“Models” Comprising Muscle Phenotypes
Congenital disorders affecting bone or muscle are often asso-
ciated with deficits in the other tissue as well. For example,
reduced muscle capacity and strength have been observed in
children with osteogenesis imperfecta (OI) [41, 43], where the
primary defect comprises the skeletal system. About 85% of
the OI cases are caused by mutations in the COL1A1 and
Table 2 Overlapping genes between different bone parameters and different muscle-related traits
Muscle-related trait Gene eBMD P value Muscle-related traits P value Reference
Bone mineral density
Total body lean mass MC4R 2.0 × 10−15 1.0 × 10−18 Karasik et al. 2019
Total body lean mass FTO 1.6 × 10−26 1.4 × 10−09 Zillikens et al. 2017
Hand grip strength IRS1 4.7 × 10−08 1.5 × 10−11 Zillikens et al. 2017
Hand grip strength MGMT 2.3 × 10−22 1.0 × 10−13 Tikkanen et al. 2018
Hand grip strength TCF4 9.4 × 10−10 5.9 × 10−15 Tikkanen et al. 2018
Hand grip strength TMEM18 2.0 × 10−11 5.4 × 10−22 Tikkanen et al. 2018
Hand grip strength LINC01104 7.9 × 10−11 3.1 × 10−09 Tikkanen et al. 2018
Hand grip strength MC4R 2.0 × 10−15 2.1 × 10−19 Tikkanen et al. 2018
Hand grip strength PEX14 6.7 × 10−13 5.6 × 10−11 Willems et al. 2017
Hand grip strength SLC8A1 7.4 × 10−38 7.7 × 10−09 Willems et al. 2017
Hand grip strength TGFA 9.3 × 10−19 4.8 × 10−13 Willems et al. 2017
Bivariate analysis with bone strength index
Appendicular lean mass FADS1 pb = 1.6 × 10
−07 Han et al. 2012
Bivariate analysis with appendicular bone size
Appendicular lean mass GLYAT pb = 1.8 × 10
−06 Guo et al. 2013
pb bivariate p value for bone/muscle pair, eBMD estimated bone mineral density
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COL1A2 genes. These mutations affect the production of the
α1/α2 chains of type 1 collagen, an important structural com-
ponent of the bone, skin, tendons, ligaments, and other con-
nective tissues [44]. Animal studies have also observed mus-
cle weakness in OI mice [45], providing additional evidence
for the muscle abnormalities in OI. The exact mechanisms
leading to muscle weakness are yet unclear but they can be
result of intrinsic muscle factors or direct paracrine effects of
the abnormal bone matrix (i.e., increased TGF-β signaling in
OI decreases lean mass).
Further, muscle abnormalities have been also noted in in-
dividuals with hypophosphatemic rickets; hereditary phos-
phate wasting disorders commonly caused by point mutations
in PHEX, FGF23, and DMP1 genes. Children carriers of any
of these mutations have soft bones (rickets), growth retarda-
tion, poor dental development, and elevated serum FGF23
levels [46]. It has been shown that accumulation of FGF23
is strongly associated with muscle function abnormalities in
humans [47, 48]. Additionally, murine models have shown
reduced grip strength and impaired muscle forces in the Hyp
(model of PHEX deficiency) and Dmp1 null (DMP1 deficien-
cy) mice [49]. However, the underlying mechanisms leading
to skeletal muscle abnormalities in individuals with
hypophosphatemic rickets have not been characterized.
Human and Animal Knock-out Models
of Muscle Comprising Bone Phenotypes
Disorders of muscle often present with bone abnormalities. For
example, in Duchenne muscular dystrophy (DMD) and Becker
muscular dystrophy, the primary defect leading to disease path-
ogenesis is degeneration of striated muscle. The mutations in the
DMD gene encode the dystrophin protein, causing Duchenne
and Becker muscular dystrophies. Yet, impairment of bone
health in the form of low BMD and increased incidence of bone
fractures are well-recognized clinical components of the DMD
phenotype [50–52]. The deleterious effects of DMDon bone can
be mediated by several mechanisms. These include downstream
functional effects on bone involving the nuclear factor of κB
pathway and cytokine-mediated (IL-6) activation of osteopontin
(OPN); disturbances of calciummetabolism; deterioration of bio-
mechanical stimuli with disease progression, side effects of cor-
ticosteroid treatment and many comorbidity processes derived
from the disease. Also, other single-gene disorders including
those derived from mutations inMTM1, RYR1, andDNM2 have
been implicated in the alteration of skeletal muscles. These con-
genital myopathies are characterized by an alteration in the con-
tractile apparatus of the muscle (myofibers) followed by loss of
muscle mass, increased muscle weakness, and decrease in bone
mass. However, due to the complex interplay between muscle
and bone, it is not clear if these changes in bonemass are result of
the decreased mechanical loading, the muscular paracrine effect,
the shared biology, or combination of all of these factors.
Another example of a potentially pleiotropic gene is the
myostatin (MSTN, a.k.a. growth and differentiation factor 8,
GDF8) gene, a member of the TGF-β superfamily, which is
secreted primarily by the skeletal muscle cells [53]. Point mu-
tations in MSTN lead to decreased production of functional
myostatin causing muscle hypertrophy in humans and animals
[54]. Recently, the relationship between myostatin and bone
has been actively investigated in animal models.MSTN deple-
tion leads to increased BMD and strength through many dif-
ferent pathways. First and foremost, the loss of myostatin is
followed by doubling of the skeletal muscle mass, which in-
creases mechanical loading on bone. However, the increase in
leanmass can also have indirect positive effects on the bone by
increasing IGF-1 levels [55]. Such studies have found that
inhibition of the myostatin pathway increases proliferation
and differentiation of osteoprogenitor cells and leads to bone
mass accrual [56]. Further, it has been shown that
haploinsufficiency of myostatin protects against aging-related
declines inmuscle function and enhances the longevity of mice
[57]. This suggests that, beyond a known effect of myostatin
on bone [58], there is also a systemic effect of this gene.
Further, myostatin binds to the soluble activin type IIB re-
ceptor (ACVR2B) which forms an activin receptor complex
with activin type 1 serine/threonine kinase receptors
(ACVRs). Loss of function of activin type I receptor
(ACVR1) in osteoblasts increases bone mass and activates ca-
nonical Wnt signaling through suppression of the Wnt inhibi-
tors SOST and DKK1 [59••]. Recently, a study has also shown
that myostatin inhibits osteoblastic differentiation by suppress-
ing osteocyte-derived exosomal microRNA-218, suggesting a
possible novel mechanism in the bone-muscle crosstalk [60].
Myocyte enhancer factor-2 (MEF2C) is a member of the
MADS-box superfamily of transcriptional regulatory proteins
relevant for skeletal muscle development, sarcomeric gene
expression, and fiber type control. MEF2C directly regulates
myomesin gene transcription and loss of Mef2c in skeletal
muscle results in improper sarcomere organization and disor-
ganized myofibers. Recent studies have found that a super
activating form of MEF2C causes precocious chondrocyte
hypertrophy, ossification of growth plates, and dwarfism
[61]. Mef2c+/− presented lack of ossification within the ster-
num. Mef2cloxP/KO; Twist2-Cre mice had shortened limbs
from birth [61]. Moreover, the MEF2 activity is enhanced by
the increase in mitogen-activated protein kinases (MAPKs)
and decrease in histone deacetylases (HDACs). HDAC inhib-
itors have been tested in a muscular dystrophy model in mice
which promoted the formation of muscles with increased
cross-sectional area [62]. Interestingly, HDAC5 part of the
HDAC family is a known BMD locus [8].
Last but not least, GWAS studies have identified variants in
FAM210A as strongly associated with fracture risk but less
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strongly with BMD. Moreover, SNPs near FAM210A were
nominally (p < 0.05) associated with lean mass in adults [1].
Interestingly, a recent study in mice has shown that Fam210a
was expressed in muscle mitochondria and cytoplasm but not
in bone [1]. Notably, grip strength and limb lean mass were
reduced in both tamoxifen-inducible Fam210a homozygous
global knockout mice (TFam210a−/−) and skeletal muscle
cell-specific knockout mice (Fam210aMus−/−). Moreover,
microarray analysis showed decreased levels of Myog and
Chdh15, transcription factors relevant for myoblast differenti-
ation, and terminal muscle differentiation, respectively. Also,
decreased BMD, bone biomechanical strength and bone for-
mation, and elevated osteoclast activity were observed in
TFam210a−/−mice [1]. Furthermore, the authors showed that
Mmp12 was increased in muscle cells of TFam210aMus −/−
mice, which can enhance osteoclast function in bone.
Therefore, Fam210a, while being expressed in muscle, plays
an influential role on bone quality and quantity.
Muscle and Bone: Beyond Biomechanics
Multiple metabolic communications have been identified be-
tween bone and muscle in humans and rodents. There are nu-
merous indications that the muscle “secretome” contains
osteoinducer and osteoinhibitor myokines [63]; it also seems
likely that bone cells secrete myoinducer and myoinhibitor
osteokines [64]. The skeletal muscle secretome accounts for var-
ious molecules that affect bone including insulin-like growth
factor-1 (IGF1), fibroblast growth factor (FGF2), interleukins
(IL6, IL15), myostatin, osteoglycin, osteoactivin, and others
(reviewed by [64]). Even though studies on the potential effects
of bone on muscle metabolism are still sparse, a few osteokines
have been identified. Prostaglandin E2 (PGE2) andWNT family
member 3A (WNT3A), which are secreted by osteocytes, are
thought to impact skeletal muscle cells. Interestingly, WNT3A
and several other WNT factors have been identified in GWAS
of BMD. Also, osteocalcin and IGF-1, which are produced by
osteoblasts, and sclerostin, which is secreted by osteocytes and
osteoblasts, exert effects on muscle cells. Further, bones and
muscles are controlled by mitochondrial genetics that standard
GWAS cannot reliably scrutinize given the sparse number of
mitochondrial markers on genotyping arrays and the difficulties
to quantifying mitochondrial heteroplasmy. Previous studies
have revealed the critical role of mitochondria in the differentia-
tion of multiple cell types, including cardiomyocytes [65] and
myoblasts [66]. Additionally, osteoporosis and sarcopenia seem
to be more prevalent among patients with mitochondrial disor-
ders. Thus, refined GWAS efforts can help understand the under-
lying mechanisms of the mitochondria, using intensity-based as-
sessments of mitochondrial copy number. In addition to the mi-
tochondrial metabolism, the genes controlling overall energyme-
tabolism might also exert an impact on bone and muscle.
Interestingly, skeletal muscle-specific disruption of the circadian
rhythms by Bmal1 deletion has been shown to disrupt skeletal
musclemetabolism [67], whereas BMAL1 deficiency results in a
low bone mass phenotype [68]. However, this gene has not yet
been identified by any GWAS on BMD.
The Potential of Genetic Discoveries to Guide
Drug Target Identification
Incorporating genetic information in the drug discovery pro-
cess can improve disease-specific drug target identification
and validation. Combining drug mechanisms with genetic
mechanistic information increases the success in drug discov-
ery over approaches that do not include genetic information,
especially for drug targets related to musculoskeletal (BMD),
metabolic, and blood traits [69].
From the molecular factors discussed above, two have been
followed as potential drug targets. It has been well established
that myostatin is a negative regulator of muscle and bone
mass. Therefore, there is hope that studies into myostatin in-
hibitors may have therapeutic application in treating muscle-
wasting diseases such asmuscular dystrophy. Bialek et al. [58]
have investigated the role of myostatin by administrating
myostatin neutralizing antibody (Mstn-mAb) or soluble
myostatin decoy receptor (ActRIIB-Fc) in young adult mice.
Interestingly, while both antibodies increased muscle mass,
only ActRIIB-Fc also increased bone mass. Thus, a therapeu-
tic agent that has this dual effect represents a potential ap-
proach for the simultaneous treatment of osteoporosis and or
sarcopenia. Another potential target is FGF23. Currently, clin-
ical trials of neutralizing anti-FGF23 antibody for patients
with FGF23-related hypophosphatemic diseases are ongoing.
First of all, FGF23 production is stimulated through signaling
acting through the FGF receptor. It has also been shown that
repeated administration of FGF receptor inhibitors causes in-
creased bone growth and mineralization in Hyp mice [70].
Similarly, weekly injection of FGF23 antibodies increased
BMD in Hyp mouse, while with a higher dose, there was also
an increase in grip strength. To note, in a phase I clinical trial,
administration of various amounts of anti-FGF23 antibodies
increased tubular maximum transport of phosphate per glo-
merular filtration rate (TmP/GFR) in adult patients with X-
linked hypophosphatemia (XLH) [71, 72]. Nevertheless, it
needs to be tested if anti-FGF23 antibody can improve or cure
rickets/osteomalacia or their clinical presentations such as
bone pain and muscle weakness. Although the clinical impli-
cations of these findings are still far-reaching, both examples
illustrate the diverse opportunities for the characterization of
drug targets that can prevent muscle and bone abnormalities.
The approach is not free of limitations, as genetically derived
targets may also have undesired secondary effects. For exam-
ple, MEF2C has been suggested as novel drug target for
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therapeutically enhancing muscle performance. Targeting these
genesmay have a significant impact on the treatment of muscle.
However, MEF2C also is related with pathological cardiac hy-
pertrophy. Hence, off-target effects can be considerable. The
key will be to improve muscle performance and prevent
cardiotoxicity at the same time when targeting these genes
[73]. Either way, this also illustrates the potential of the genetic
evidence underlying drug targets to typify the presence of ad-
verse effects before embarking on expensive experimentation.
Summary and Future Directions
Overall, there are many evolutionary, biological, and clinical
factors that couple the pathogenesis of sarcopenia and osteo-
porosis. Both muscle and bone also act as endocrine organs
[74, 74] and share common genetic influences. Although chal-
lenging, there is a growing research enterprise aimed at eluci-
dating and unraveling new mechanisms of muscle-bone
crosstalk. Many questions still remain unanswered and need
to be addressed through the integration of in vitro and in vivo
models. For example, what are the exact mechanisms under-
lying the cross-organ effects? Do muscle factors, by stimulat-
ing bone metabolism, also lead to increased release of
myoinducer and myoinhibitor osteokines? More importantly,
the question remains as how the aging process influences
muscle and bone metabolism, including the underlying mo-
lecular factors. Further, the role of central mechanisms in co-
regulation of the musculoskeletal system needs to be investi-
gated in its entirety rather than its parts. Finally, the study of
pleiotropy may provide novel insights into disease pathophys-
iology with the potential of leading to the identification of
drug targets that simultaneously prevent or treat both diseases.
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